CN1092045C - 泡状复合物及其制备和应用方法 - Google Patents

泡状复合物及其制备和应用方法 Download PDF

Info

Publication number
CN1092045C
CN1092045C CN98810484A CN98810484A CN1092045C CN 1092045 C CN1092045 C CN 1092045C CN 98810484 A CN98810484 A CN 98810484A CN 98810484 A CN98810484 A CN 98810484A CN 1092045 C CN1092045 C CN 1092045C
Authority
CN
China
Prior art keywords
nucleic acid
composition
local anesthetic
lamellar vesicles
protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN98810484A
Other languages
English (en)
Chinese (zh)
Other versions
CN1277549A (zh
Inventor
R·B·西卡雷利
C·萨蒂什钱德拉
C·J·帕丘克
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wyeth LLC
Original Assignee
American Home Products Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by American Home Products Corp filed Critical American Home Products Corp
Publication of CN1277549A publication Critical patent/CN1277549A/zh
Application granted granted Critical
Publication of CN1092045C publication Critical patent/CN1092045C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/70—Nanostructure
    • Y10S977/773—Nanoparticle, i.e. structure having three dimensions of 100 nm or less
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/905—Specially adapted for travel through blood circulatory system
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/906—Drug delivery
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/906—Drug delivery
    • Y10S977/907—Liposome
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/915—Therapeutic or pharmaceutical composition
    • Y10S977/916—Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Dispersion Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Mycology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CN98810484A 1997-04-30 1998-04-30 泡状复合物及其制备和应用方法 Expired - Fee Related CN1092045C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US4512297P 1997-04-30 1997-04-30
US60/045,122 1997-04-30

Publications (2)

Publication Number Publication Date
CN1277549A CN1277549A (zh) 2000-12-20
CN1092045C true CN1092045C (zh) 2002-10-09

Family

ID=21936112

Family Applications (1)

Application Number Title Priority Date Filing Date
CN98810484A Expired - Fee Related CN1092045C (zh) 1997-04-30 1998-04-30 泡状复合物及其制备和应用方法

Country Status (12)

Country Link
US (2) US6217900B1 (https=)
EP (1) EP0986372B1 (https=)
JP (1) JP2002508747A (https=)
KR (1) KR100554344B1 (https=)
CN (1) CN1092045C (https=)
AT (1) ATE446372T1 (https=)
AU (1) AU728115C (https=)
BR (1) BR9809006B1 (https=)
CA (1) CA2285298C (https=)
DE (1) DE69841251D1 (https=)
ES (1) ES2333282T3 (https=)
WO (1) WO1998048780A1 (https=)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999061032A1 (en) * 1998-05-25 1999-12-02 Nippon Shinyaku Co., Ltd. Process for producing composite preparation containing nucleic acid
EP2314700A1 (en) * 1999-01-28 2011-04-27 Medical College of Georgia Research Institute, Inc Composition and method for in vivo and in vitro attenuation of gene expression using double stranded RNA
EP1097993A3 (en) * 1999-11-05 2004-01-07 National Institute of Advanced Industrial Science and Technology Functional ribozyme chimeric molecules capable of sliding
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
US7461046B2 (en) * 2002-02-07 2008-12-02 The University Of Utah Research Foundation Method for creating and using a treatment protocol
US20040180438A1 (en) * 2002-04-26 2004-09-16 Pachuk Catherine J. Methods and compositions for silencing genes without inducing toxicity
WO2003093449A2 (en) * 2002-05-06 2003-11-13 Nucleonics, Inc. Methods for delivery of nucleic acids
JP2005529959A (ja) * 2002-06-14 2005-10-06 マイラス コーポレイション 細胞へのポリヌクレオチドの伝達をするための新規な方法
EP1540004A4 (en) * 2002-07-31 2007-10-03 Nucleonics Inc DOUBLE-STRING RNA STRUCTURES AND CONSTRUCTS AND METHOD FOR THE PRODUCTION AND USE THEREOF
WO2004073631A2 (en) * 2003-02-14 2004-09-02 Combinatorx, Incorporated Combination therapy for the treatment of neoplasms
HUE042261T2 (hu) 2003-06-12 2019-06-28 Alnylam Pharmaceuticals Inc Gén kikapcsolásra alkalmas konzervált HBV és HCV szekvenciák
TW200613554A (en) 2004-06-17 2006-05-01 Wyeth Corp Plasmid having three complete transcriptional units and immunogenic compositions for inducing an immune response to HIV
JP2008514202A (ja) 2004-09-24 2008-05-08 ニュークレオニクス・インコーポレイテッド Ｒｎａｉによる一本鎖ウイルスの逆鎖複製中間体のターゲティング
EP2316942B1 (en) 2004-12-22 2021-04-21 Alnylam Pharmaceuticals, Inc. Conserved hbv and hcv sequences useful for gene silencing
HRP20140338T1 (hr) 2005-07-25 2014-06-20 Emergent Product Development Seattle, Llc Smanjenje broja b-stanica upotrebom molekula koje se specifiäśno vežu na cd37 i cd20
WO2007146968A2 (en) 2006-06-12 2007-12-21 Trubion Pharmaceuticals, Inc. Single-chain multivalent binding proteins with effector function
DK2041270T3 (da) 2006-07-13 2014-01-27 Wyeth Llc Fremstilling af glycoproteiner
EP2799547B1 (en) 2006-11-08 2016-12-21 Veritas Bio, LLC In Vivo Delivery of RNA to a Target Cell
JP2010532764A (ja) * 2007-07-06 2010-10-14 トゥルビオン・ファーマシューティカルズ・インコーポレーテッド Ｃ末端に配置された特異的結合性ドメインを有する結合性ペプチド
EP2365003A1 (en) 2008-04-11 2011-09-14 Emergent Product Development Seattle, LLC CD37 immunotherapeutic and combination with bifunctional chemotherapeutic thereof
JP5883381B2 (ja) 2009-05-05 2016-03-15 ミラゲン セラピューティクス，インコーポレイテッド 親油性ポリヌクレオチド接合体
CA2765129A1 (en) 2009-06-08 2010-12-16 Miragen Therapeutics Chemical modification motifs for mirna inhibitors and mimetics
WO2011121074A1 (en) * 2010-04-01 2011-10-06 Pharmanest Ab Thermogelling anaesthetic compositions
WO2012061810A1 (en) 2010-11-05 2012-05-10 Miragen Therapeutics Base modified oligonucleotides
EA201370139A1 (ru) 2010-12-15 2013-10-30 Мираген Терапеутикс Ингибиторы микро-рнк, содержащие закрытые нуклеотиды
CA2832899A1 (en) 2011-04-12 2012-10-18 Beth Israel Deaconess Medical Center, Inc. Micro-rna inhibitors and their uses in disease
EP2755663A4 (en) 2011-09-13 2015-10-07 Ottawa Hospital Res Inst MicroRNA Inhibitors
US9388408B2 (en) 2012-06-21 2016-07-12 MiRagen Therapeutics, Inc. Oligonucleotide-based inhibitors comprising locked nucleic acid motif
CA2902571A1 (en) 2013-03-15 2014-09-18 MiRagen Therapeutics, Inc. Bridged bicyclic nucleosides
EP3068783B1 (en) 2013-11-15 2020-09-23 The Board of Trustees of the Leland Stanford Junior University Agonists of hypocretin receptor 2 for use for treating heart failure
US10772974B2 (en) 2013-11-18 2020-09-15 Beth Israel Deaconess Medical Center, Inc. Compositions and methods for cardiac regeneration
CN108064175A (zh) 2014-08-04 2018-05-22 米拉根医疗股份有限公司 Myh7b的抑制剂及其用途
AU2015315298B2 (en) 2014-09-08 2020-05-14 MiRagen Therapeutics, Inc. miR-29 mimics and uses thereof
US9885042B2 (en) 2015-01-20 2018-02-06 MiRagen Therapeutics, Inc. miR-92 inhibitors and uses thereof
MX368314B (es) 2015-06-05 2019-09-27 Miragen Therapeutics Inc Inhibidores del mir-155 para tratar linfoma cutáneo de células t (ctcl).
EP3352760B1 (en) 2015-09-21 2026-03-11 Aptevo Research and Development LLC Cd3 binding polypeptides
WO2017087486A1 (en) 2015-11-16 2017-05-26 Ohio State Innovation Foundation Methods and compositions for treating disorders and diseases using survival motor neuron (smn) protein
EP3472193A4 (en) 2016-06-20 2020-01-08 The Board of Trustees of the Leland Stanford Junior University CIRCULAR RNA AND THEIR USE IN IMMUNOMODULATION
UY37376A (es) 2016-08-26 2018-03-23 Amgen Inc Construcciones de arni para inhibir expresión de asgr1 y métodos para su uso
ES2659845B1 (es) 2016-09-19 2019-01-04 Univ Valencia Modulación de microRNAs contra la distrofia miotónica tipo 1 y antagonistas de microRNAs para ello
AR113490A1 (es) 2017-12-12 2020-05-06 Amgen Inc CONSTRUCCIONES DE ARNi PARA INHIBIR LA EXPRESIÓN DE PNPLA3 Y MÉTODOS DE USO DE LAS MISMAS
BR112020018705A2 (pt) 2018-03-14 2021-01-05 Beth Israel Deaconess Medical Center Inibidores de microrna 22
CN113166761B (zh) 2018-12-10 2025-09-09 美国安进公司 用于抑制pnpla3表达的rnai构建体
EP3894554A1 (en) 2018-12-10 2021-10-20 Amgen Inc. Chemically-modified rnai constructs and uses thereof
TW202111124A (zh) 2019-05-30 2021-03-16 美商安進公司 用於抑制ｓｃａｐ表現之ｒｎａｉ構建體及其使用方法
WO2021030613A1 (en) 2019-08-13 2021-02-18 Amgen Inc. Rnai constructs for inhibiting slc30a8 expression and methods of use thereof
US20230078200A1 (en) 2019-12-09 2023-03-16 Amgen Inc. RNAi CONSTRUCTS AND METHODS FOR INHIBITING LPA EXPRESSION
WO2021234607A1 (en) 2020-05-20 2021-11-25 St. Jude Children's Research Hospital Detection of alzheimer's disease using specific biomarkers
MX2022015169A (es) 2020-06-01 2023-07-03 Amgen Inc Constructos de arni para inhibir la expresion de hsd17b13 y metodos de uso de los mismos.
EP3929295A1 (en) 2020-06-26 2021-12-29 Universitat Pompeu Fabra Artificial rnas for modulating rna fragments
PE20230993A1 (es) 2020-08-13 2023-06-23 Amgen Inc Construcciones de iarn y metodos para inhibir la expresion de marc1
WO2022098841A1 (en) 2020-11-05 2022-05-12 Amgen Inc. METHODS FOR TREATING ATHEROSCLEROTIC CARDIOVASCULAR DISEASE WITH LPA-TARGETED RNAi CONSTRUCTS
WO2023278295A1 (en) 2021-06-29 2023-01-05 The Broad Institute, Inc. Compositions and methods for ameliorating anterodorsal thalamus hyperexcitability
CN118556125A (zh) 2021-10-05 2024-08-27 美国安进公司 用于增强寡核苷酸化合物的基因沉默活性的组合物和方法
CA3235262A1 (en) 2021-10-22 2023-04-27 Amgen Inc. Rnai constructs for inhibiting gpam expression and methods of use thereof
IL317825A (en) 2022-07-25 2025-02-01 Amgen Inc RNA interference constructs and methods for inhibiting fam13a expression
EP4353823A1 (en) 2022-10-12 2024-04-17 Resalis Therapeutics S.r.l. Inhibitors of micro-rna 22
AR131389A1 (es) 2022-12-16 2025-03-12 Amgen Inc CONSTRUCTOS DE ARNi PARA INHIBIR LA EXPRESIÓN DE TTR Y MÉTODOS DE USO DE LOS MISMOS
WO2025260042A1 (en) 2024-06-14 2025-12-18 Amgen Inc. Rnai constructs and methods for inhibiting cnr1 expression
WO2026006275A2 (en) 2024-06-26 2026-01-02 Amgen Inc. Rnai constructs and methods for inhibiting expression of inhbe

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5514788A (en) * 1993-05-17 1996-05-07 Isis Pharmaceuticals, Inc. Oligonucleotide modulation of cell adhesion

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4945050A (en) 1984-11-13 1990-07-31 Cornell Research Foundation, Inc. Method for transporting substances into living cells and tissues and apparatus therefor
US5948441A (en) * 1988-03-07 1999-09-07 The Liposome Company, Inc. Method for size separation of particles
US5593972A (en) 1993-01-26 1997-01-14 The Wistar Institute Genetic immunization
AU675702B2 (en) * 1993-01-26 1997-02-13 Leslie R. Coney Compositions and methods for delivery of genetic material
DK0800579T3 (da) * 1994-12-30 2002-09-09 Chiron Corp Kombinations-gen-leveringsvehikler
KR20140137679A (ko) 2013-05-23 2014-12-03 삼성전자주식회사 카드 소켓 장치

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5514788A (en) * 1993-05-17 1996-05-07 Isis Pharmaceuticals, Inc. Oligonucleotide modulation of cell adhesion

Also Published As

Publication number Publication date
EP0986372B1 (en) 2009-10-21
DE69841251D1 (de) 2009-12-03
AU728115B2 (en) 2001-01-04
AU728115C (en) 2004-01-22
EP0986372A1 (en) 2000-03-22
CA2285298A1 (en) 1998-11-05
WO1998048780A1 (en) 1998-11-05
CN1277549A (zh) 2000-12-20
AU7272498A (en) 1998-11-24
KR100554344B1 (ko) 2006-02-22
CA2285298C (en) 2008-12-23
US6217900B1 (en) 2001-04-17
ATE446372T1 (de) 2009-11-15
ES2333282T3 (es) 2010-02-18
EP0986372A4 (en) 2002-06-19
BR9809006A (pt) 2000-08-08
BR9809006B1 (pt) 2010-02-09
US6383512B1 (en) 2002-05-07
KR20010020161A (ko) 2001-03-15
JP2002508747A (ja) 2002-03-19

Similar Documents

Publication Publication Date Title
CN1092045C (zh) 泡状复合物及其制备和应用方法
CN1109046C (zh) 细胞毒t淋巴细胞应答的诱导
CN1138533C (zh) 脂质体
CN100340289C (zh) 增强核酸接种免疫应答的方法
US20190275145A1 (en) Particulate vaccine formulations
CN1088599C (zh) 包括一种抗原或包含氨基酸序列化合物的体内发生器的治疗性组合物
CN1180697A (zh) 用于基因治疗的阳离子类脂
HK1039072A1 (zh) 佐剂组合物及其使用方法
AU745805B2 (en) Compositions and methods for delivery of genetic material
JP2014508734A (ja) フルオロカーボン連結ペプチド製剤
CN1882358A (zh) 添加烷基磷脂酰胆碱作为辅药的疫苗组合物
CN1479632A (zh) 用于将核酸导入细胞的复合物
CN1464789A (zh) 抗流感病毒疫苗及所述病毒疫苗的制备方法
CN1638780A (zh) 用脉冲电场进行颗粒辅助的多核苷酸免疫的方法
CN1744883A (zh) 获得蜗形结构的方法、其疫苗组合物、佐剂以及中间体
JPWO2022244825A5 (https=)
CN1414864A (zh) 粘粒dna构建体以及制备和使用该构建体的方法
TWI756948B (zh) 胜肽奈米管之製備方法、用途及其免疫組成物
CN1726183A (zh) 阳离子心磷脂类似物及其应用
CN1829535A (zh) 用于接种的sphingoid聚烷基胺缀合物
HK40127068A (zh) 脂质纳米颗粒
CN1720998A (zh) 猪白细胞介素－2基因抗感染制剂的制备及应用
WO2017205550A1 (en) Immunogenic cochleates and methods of use
HK1008226B (en) Induction of cytotoxic t-lymphocyte responses

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C17 Cessation of patent right
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20021009

Termination date: 20120430